Literature DB >> 2869683

Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine.

J Ribe, K J Benkov, S N Thung, S C Shen, N S LeLeiko.   

Abstract

Sulfasalazine (salicylazosulfapyridine) is a commonly prescribed oral medication for inflammatory bowel disease. We report a case of a 15-yr-old boy with ulcerative colitis who developed a generalized hypersensitivity reaction with a serum sickness-like syndrome and severe hepatotoxicity while taking sulfasalazine, perphenazine, and amitriptyline. The injury to the liver persisted for 5 months after withdrawal of the drugs, and the patient died of terminal hepatic failure with massive hepatic necrosis. Severe hepatic toxicity to sulfasalazine is uncommon, but it can be fatal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869683

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  The three week sulphasalazine syndrome.

Authors:  H Brooks; H G Taylor; F E Nichol
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

2.  Drug-induced hypersensitivity syndrome associated with reactivation of human herpesvirus 6 presenting with severe hepatic injury.

Authors:  Hideaki Miura; Masayuki Nakano; Naoki Yoshimura; Shigehiro Kitamura; Haruki Yamada; Masakazu Takazoe
Journal:  Clin J Gastroenterol       Date:  2008-09-03

Review 3.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28

4.  Sulphasalazine in the treatment of pauciarticular-onset juvenile chronic arthritis.

Authors:  A Gedalia; J Barash; J Press; D Buskila
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

5.  Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.

Authors:  L G Quallich; J Greenson; H M Haftel; R J Fontana
Journal:  BMC Gastroenterol       Date:  2001-08-29       Impact factor: 3.067

6.  Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity.

Authors:  Sean Hammond; Anna Olsson-Brown; Sophie Grice; Andrew Gibson; Joshua Gardner; Jose Luis Castrejón-Flores; Carol Jolly; Benjamin Alexis Fisher; Neil Steven; Catherine Betts; Munir Pirmohamed; Xiaoli Meng; Dean John Naisbitt
Journal:  Toxicol Sci       Date:  2022-02-28       Impact factor: 4.849

7.  Drug hypersensitivity syndrome induced by sulfasalazine: A case report.

Authors:  Dong-Hui Chen; Hai-Rong Zhou; Yong-Gang Zhang; Guan-Yuan Shen; Chong Xu; Chun-Li Guan
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

8.  Case of relapsing sulfasalazine-induced hypersensitivity syndrome upon re-exposure.

Authors:  Jason Winward; Laurel Lyckholm; Samuel M Brown; Mohamad Mokadem
Journal:  BMJ Case Rep       Date:  2020-09-15

9.  Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin.

Authors:  J L Huang; I J Hung; L C Chen; W Y Lee; C Hsueh; K H Hsieh
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 3.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.